Investigators compared outcomes of chemotherapy conditioning with total body irradiation prior to hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.
Maintenance therapy with oral azacitidine leads to longer overall survival in older patients with acute myeloid leukemia.
Despite the clinical success of combination therapy with immune checkpoint inhibitors many research questions still remain.
Researchers reviewed the challenges and future developments in ICI combination therapies for the treatment of patients with acute myeloid leukemia and myelodysplastic syndromes.
Among patients with myelodysplastic syndrome, long noncoding RNA KIAA0125 may predict poorer overall survival and leukemia-free survival.
Intermittent dosing of the targeted agent may overcome toxicity limitations, providing a potential therapy for a hard-to-treat multiple myeloma.
Combination venetoclax, bortezomib, and dexamethasone may improve response rates among patients with relapsed/refractory MM with specific biomarkers.
Among patients with AML, maintenance therapy with rhG-CSF plus decitabine led to fewer relapses compared with patients who received no treatment after HSCT.
CP-CML patients who remain on first-line TKI therapy have better clinical responses than patients who switch within the first 3 years.
Patients with relapsed/refractory AML who do not respond to venetoclax-based salvage therapy may have a response to intensified chemotherapy.
